CurrentBlue Cross Blue Shield - MassachusettsPolicy 555

555 Identification of Microorganisms Using Nucleic Acid Probe prn.pdf

This medical policy defines medical necessity and investigational determinations for nucleic acid testing using direct, amplified, or quantitative probe techniques (including viral load quantification) for identification of a range of microorganisms, applicable to Commercial and Medicare members of Blue Cross Blue Shield Massachusetts. It also provides coding guidance, inpatient preauthorization requirements, and lists CPT codes considered medically necessary versus investigational.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

Policy555 Identification of Microorganisms Using Nucleic Acid Probe prn.pdf

Policy CodePolicy 555

Change TypeCoding clarifications; Addition of Mycoplasma genitalium; Literature update

Effective Date

Next Review Date

Key ActionPrecertification/preauthorization is required for all products if the nucleic acid probe procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

Clarified coding information.

Mycoplasma genitalium added to list of medically necessary nucleic acid testing.

Policy updated with literature review through April 4, 2025; references added; policy statements unchanged.

30+Microorganisms listed (medically necessary + viral list)

20+CPT codes medically necessary

20+

Coverage Summary

This policy defines medical necessity and investigational determinations for nucleic acid testing using direct, amplified, or quantitative (viral load) probe techniques to identify microorganisms for Commercial and Medicare members of Blue Cross Blue Shield Massachusetts. It includes coding guidance, inpatient preauthorization requirements, and lists CPT codes designated as medically necessary versus investigational.

Coverage stance: mixed. High-level takeaways: direct or amplified probe testing (without quantification) is medically necessary for a specified list of microorganisms; direct/amplified testing with or without quantification is medically necessary for certain viral agents; quantification (viral load) is investigational for agents not listed as medically necessary; several multitarget panels (notably CNS, GI, and many urinary panels) are considered investigational.

Scope-specific counts

Microorganisms listed (medically necessary + viral list)30+

CPT codes medically necessary20+

CPT codes investigational20+

PreauthorizationInpatient PA required

References listed18

Medical-Necessity Criteria

Medically Necessary (Direct or Amplified Probe, without quantification)

Covered when ALL of the following are met:

ALL of the following

Bartonella henselae or quintana
Bordetella pertussis
Candida species
Chlamydia pneumoniae
Chlamydia trachomatis

Not Covered / Investigational

Per the policy, quantification (viral load) is considered investigational for microorganisms that are not included in the lists of agents for which probes (with or without quantification) are designated medically necessary. The policy explicitly notes that panels such as the central nervous system (CNS) pathogen panel, gastrointestinal (GI) pathogen panel, and urinary pathogen panels are considered investigational.

Background evidence supporting these investigational determinations includes limited or insufficient evidence of net health outcome improvement for CNS and GI panels, and concerns about panel sensitivity/false positives and unclear clinical utility in most settings.

Coding

Medically necessary CPT codes (selected list)CPTCovered

87471	Bartonella henselae and Bartonella quintana, amplified probe technique
87480	Candida species, direct probe technique
87481	Candida species, amplified probe technique
87485	Chlamydia pneumoniae, direct probe technique
87486	Chlamydia pneumoniae, amplified probe technique
87487	Chlamydia pneumoniae, quantification
87490	Chlamydia trachomatis, direct probe technique
87491	Chlamydia trachomatis, amplified probe technique
87493	Clostridium difficile, toxin gene(s), amplified probe technique
87495	Cytomegalovirus, direct probe technique

1–10 of 48

1/5

The above medical necessity criteria MUST be met for the following CPT codes to be covered: see the policy criteria and coding-specific mappings for the list of CPT codes that are considered medically necessary when the policy conditions are satisfied.

Provider Actions

Prior Authorization

Inpatient precertification required

Precertification/preauthorization is required for all products if the nucleic acid probe procedure is performed inpatient.

Applies to all products when performed inpatient

Documentation Required

Medical necessity documentation

Medical necessity criteria listed in the policy MUST be met and documented for the listed CPT codes to be covered for Commercial and Medicare members.

Criteria MUST be met and documented for listed CPT codes for Commercial and Medicare members

Background & Evidence

Nucleic acid probes detect organism RNA or DNA and are available as direct, amplified, or quantitative techniques. Amplified methods (eg, PCR and other amplification strategies) generally provide higher sensitivity than direct probes. Quantification (eg, quantitative or real-time PCR) yields viral load measurements used for prognosis and monitoring (most commonly HIV viral load). Many commercially available tests have been combined into multiplex panels; except for certain respiratory panels, the policy considers many panels (notably CNS, GI, and urinary pathogen panels) investigational or lacking sufficient evidence of improved net health outcome.

Evidence summary

Respiratory pathogen panel outcomeRCTs and systematic reviews show improved time-to-treat, more targeted antibiotics, and reduced length of stay; evidence sufficient for net health benefit.

CNS and GI panels outcomeEvidence insufficient to determine improvement in net health outcome for CNS and gastrointestinal panels.

Key randomized/clinical studies citedBrendish et al. ResPOC Lancet Respir Med 2017; additional trials and randomized studies of multiplex/point-of-care testing referenced.

Guideline sources

Definitions

Direct probe technique: Detection methods in which nucleic acids are detected without an initial amplification step.

Amplified probe technique: Detection methods in which target, probe, or signal amplification is used to improve assay sensitivity over direct probes, without quantification.

Probe with quantification: Quantitative or real-time PCR methods that generate absolute or relative amounts of a known nucleic acid sequence in the original sample, providing viral load information for prognosis or treatment monitoring.

Preauthorization Requirements

Revision History

11/2024revised

Change recorded 11/2024 effective 11/1/2024: Mycoplasma genitalium added to list of medically necessary nucleic acid testing; clarified coding information. (Material change)

8/2025revised

Annual policy review 8/2025: Policy updated with literature review through April 4, 2025; references added; policy statements unchanged.

2025-2026clarifiedLatest

Multiple entries in 2025-2026 indicate clarified coding information; policy statements unchanged.

Coding-specific medically necessary CPT codes

Coding-specific medically necessary CPT codes (selected list). The medical necessity criteria above MUST be met for these codes to be covered for Commercial and Medicare members:

ALL of the following

87471 - Infectious agent detection by nucleic acid; Bartonella henselae and Bartonella quintana, amplified probe technique
87480 - Infectious agent detection by nucleic acid; Candida species, direct probe technique
87481 - Infectious agent detection by nucleic acid; Candida species, amplified probe technique
87485 - Chlamydia pneumoniae, direct probe technique
87486 - Chlamydia pneumoniae, amplified probe technique
87487 - Chlamydia pneumoniae, quantification
87490 - Chlamydia trachomatis, direct probe technique
87491 - Chlamydia trachomatis, amplified probe technique
87493 - Clostridium difficile, toxin gene(s), amplified probe technique
87495 - Cytomegalovirus, direct probe technique
87496 - Cytomegalovirus, amplified probe technique
87497 - Cytomegalovirus, quantification
87498 - Enterovirus, amplified probe technique (includes reverse transcription when performed)
87500 - Vancomycin resistance (eg, enterococcus species vanA, vanB), amplified probe technique
87501 - Influenza virus, includes reverse transcription when performed, amplified probe technique, each type or subtype
87502/87503 - Influenza virus, multiplex amplified probe technique (first 2 types/sub-types and additional types)
87516 - Hepatitis B virus, amplified probe technique
87517 - Hepatitis B virus, quantification
87520 - Hepatitis C, direct probe technique
87521 - Hepatitis C, amplified probe technique (includes reverse transcription when performed)
87522 - Hepatitis C, quantification (includes reverse transcription when performed)
87528 - Herpes simplex virus, direct probe technique
87529 - Herpes simplex virus, amplified probe technique
87531 - Human herpesvirus-6, direct probe technique
87532 - Human herpesvirus-6, amplified probe technique
87534 - HIV-1, direct probe technique
87535 - HIV-1, amplified probe technique (includes reverse transcription when performed)
87536 - HIV-1, quantification (includes reverse transcription when performed)
87537 - HIV-2, direct probe technique
87538 - HIV-2, amplified probe technique (includes reverse transcription when performed)
87539 - HIV-2, quantification (includes reverse transcription when performed)
87540 - Legionella pneumophila, direct probe technique
87541 - Legionella pneumophila, amplified probe technique
87550 - Mycobacteria species, direct probe technique
87551 - Mycobacteria species, amplified probe technique
87555 - Mycobacteria tuberculosis, direct probe technique
87556 - Mycobacteria tuberculosis, amplified probe technique